Welcome to our dedicated page for Cv Sciences SEC filings (Ticker: CVSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CV Sciences, Inc. (OTCQB:CVSI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports and other documents that explain its financial condition, capital structure, and material agreements. CV Sciences presents itself as a consumer wellness company focused on hemp extracts, nutraceuticals, and plant-based foods, and its filings offer detail on how this strategy is reflected in its operations and financing.
Recent Form 8-K filings describe material events such as note purchase agreements and secured promissory notes with institutional investors. These reports outline original issuance discounts, net proceeds, maturity dates, repayment schedules, and security interests in the assets of CV Sciences and its subsidiaries. They also summarize customary events of default, potential increases to outstanding balances upon default, and the circumstances under which amounts can be declared immediately due and payable.
Other 8-K filings incorporate by reference the company’s earnings press releases, which include GAAP financial statements and non-GAAP measures like Adjusted EBITDA. In these disclosures, CV Sciences explains why management uses non-GAAP metrics, how they reconcile to GAAP results, and how they are intended to highlight trends in the business.
Through Stock Titan, users can review these filings alongside AI-powered summaries that clarify key terms in note purchase agreements, security agreements, and intellectual property security agreements. The platform also helps surface important items in quarterly and annual reports, such as product sales, gross margin, operating income or loss, and cash flow trends, without requiring readers to parse every line of the underlying documents.
Investors interested in CVSI can use this page to monitor new 8-Ks and other SEC submissions as they are posted to EDGAR, while AI-generated insights provide plain-language explanations of complex financing structures and reporting conventions.
CV Sciences, Inc. reported 2025 net product sales of $13.8 million, down 12.2% from 2024, while improving gross margin to 49.0% from 45.6%. The company narrowed its net loss to $0.96 million from $2.39 million, helped by cost reductions and lower operating expenses.
The business added plant-based food and softgel manufacturing through the Cultured Foods and Elevated Softgels acquisitions and launched new brands, with products sold in about 2,500 U.S. stores and across Europe. Despite this, cash was $0.28 million and management disclosed substantial doubt about its ability to continue as a going concern, citing intense CBD competition and significant regulatory uncertainty, including a new federal “total THC” cap effective November 2026.
CV Sciences, Inc. reported 2025 revenue of $13.8 million, down from $15.7 million in 2024, but improved profitability metrics. Gross margin rose to 49.0% from 45.6%, and operating loss narrowed to $0.5 million from $2.2 million, with net loss reduced to $0.96 million.
In the fourth quarter, revenue was $3.3 million, slightly above the prior quarter, and the company generated positive adjusted EBITDA of about $0.1 million after a full-year adjusted EBITDA loss of $0.3 million. Management cut operating expenses 17.2% to $7.7 million and attributes the revenue decline mainly to temporary product outages and regulatory headwinds.
Cash ended 2025 at $0.3 million with total assets of $7.0 million and total liabilities of $5.5 million. The company highlights 39 new products since 2023, with 39% of 2025 net revenue from these launches, plus new +PlusCBD and +PlusHLTH offerings and a completed debt restructuring in early 2026 aimed at strengthening its financial position.
CV Sciences, Inc. entered into an agreement with its institutional investor to amend and restate two secured promissory notes into senior secured convertible notes. The Amended Notes now carry a fixed conversion price of $0.06 per share and are initially convertible into 37,600,000 shares of common stock.
The notes’ outstanding principal was increased by 20%, giving an aggregate principal of $2,256,000, and the company eliminated its prior obligation to make monthly redemptions before maturity. A beneficial ownership cap limits the investor to 4.99% of outstanding shares, optionally rising to 9.99% with notice.
A true-up feature aims to ensure the investor’s net sale proceeds equal the principal converted; if the aggregate shortfall across both notes exceeds $94,000, the company will issue a new senior secured convertible note, potentially due April 6, 2027, with no stated cap on shares from that note. The securities were issued without registration under the Securities Act, in reliance on Section 4(a)(2) and/or Regulation D.
CV Sciences, Inc. reported Q3 results marked by softer sales and tight liquidity while taking steps to refinance debt and reduce obligations. Product sales, net were $3.256M versus $3.865M a year ago. Gross profit was $1.579M, and the company posted a net loss of $382K compared to a loss of $456K in Q3 2024.
Cash was $381K as of September 30, 2025, with operating cash use of $53K year‑to‑date. Total assets were $6.995M and stockholders’ equity was $1.539M. The company amended a $1.6M secured note in September 2025 and paid the investor $150K; it also fully repaid a prior Streeterville note, recognizing a $37.5K gain. Subsequent to quarter‑end, it issued a new secured note with original principal of $600K for net proceeds of $300K.
Management disclosed substantial doubt about continuing as a going concern and noted new federal legislation effective November 13, 2026 that will prohibit sales of hemp‑derived products containing more than 0.4 milligrams of total THC per container, which the company is evaluating. Shares outstanding were 184,263,663 as of November 11, 2025.
CV Sciences, Inc. furnished an 8‑K announcing it issued a press release covering financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference into Item 2.02 via Item 7.01.
The release includes non‑GAAP financial measures with GAAP reconciliations and related explanations. The information is furnished, not filed, and includes forward‑looking statements that are subject to risks and uncertainties.
CV Sciences, Inc. entered into a new note purchase agreement with an institutional investor and issued a secured promissory note with an original principal amount of $600,000. After a $150,000 original issuance discount, a $150,000 payment tied to modifying a prior purchase agreement, and $13,125 of legal and other fees, the Company received net proceeds of $300,000.
The Note is secured by all of the Company’s assets and the assets and intellectual property of its subsidiaries under a Security Agreement and an Intellectual Property Security Agreement dated October 6, 2025. Monthly repayments of $46,153.85 begin on April 6, 2026, with all unpaid amounts due by April 6, 2027, and an 8% discount applies if the Note is fully repaid within six months of closing.
The Note includes customary events of default. On certain events of default, the investor may increase the outstanding balance by 20% or 5%, declare all amounts immediately due, and begin charging interest on the outstanding balance at up to 18% per annum or the maximum rate allowed by law.
CV Sciences, Inc. entered into an agreement with an institutional investor to amend its existing secured promissory note originally issued for a principal amount of $1,600,000.
The amendment extends the note’s maturity to February 12, 2027, revises the monthly principal redemptions to $106,666.67 for the first three months, then zero principal for six months, followed by $106,666.67 for the next twelve months, in each case plus any accrued but unpaid interest. As part of the revised terms, the company also agreed to pay the investor an additional $150,000 in cash, while all other provisions of the original note and purchase agreement remain in effect.